Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1199 studies found for:    ESR1
Show Display Options
Rank Status Study
1 Recruiting Study of ESR1 Mutations in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Biological: Determination of ESR1 mutations
2 Active, not recruiting An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
Condition: Oestrogen Receptor Positive Advanced Breast Cancer
Interventions: Drug: RAD001;   Drug: Exemestane
3 Completed Estrogen Receptors and Chronic Venous Disease
Conditions: Estrogen Excess;   Varicose Veins
Intervention: Procedure: Venous Surgery
4 Completed
Has Results
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Conditions: Estrogen Receptor Positive Tumor;   Breast Cancer
Interventions: Drug: eribulin mesylate;   Drug: capecitabine
5 Unknown  Validation of [18F]FES for Imaging of Brain Estrogen Receptors
Conditions: Psychiatric/Mood Disorder | Patient;   Estrogen Receptor Levels;   Premenopausal;   Postmenopausal
Intervention: Procedure: FES-PET
6 Completed
Has Results
A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED)
Condition: Postmenopause
Interventions: Drug: Comparator: placebo;   Drug: Comparator: Estrace
7 Recruiting Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen
Condition: Metastatic Breast Cancer
Interventions: Drug: Fulvestrant;   Drug: Tamoxifen
8 Not yet recruiting GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer
Condition: Advanced Estrogen Receptor Positive HER2- Breast Cancer
Interventions: Drug: GS-5829;   Drug: Exemestane;   Drug: Fulvestrant
9 Active, not recruiting Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Condition: Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Exemestane
10 Active, not recruiting BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: BKM120;   Drug: Fulvestrant;   Procedure: biopsy
11 Recruiting Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
Condition: Breast Cancer
Interventions: Drug: Fluorestradiol (FES);   Procedure: PET/CT Imaging
12 Completed Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
Condition: Hormon Receptor Positive Breast Cancer
Intervention:
13 Recruiting Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?
Conditions: Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder
Interventions: Drug: Raloxifene Hydrochloride;   Drug: Placebo
14 Recruiting Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
Condition: Female Breast Cancer
Intervention: Drug: Toremifene; Anastrozole
15 Not yet recruiting Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Phase I: estetrol;   Drug: Phase II: estetrol
16 Completed Estrogen Receptor Gene Mutations
Conditions: Mutations;   Hormones
Intervention:
17 Recruiting Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Postmenopausal;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Drug: Palbociclib;   Biological: Pembrolizumab
18 Recruiting The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: LY500307 150mg;   Drug: LY500307 75mg;   Drug: Placebo
19 Completed Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder
Interventions: Drug: Raloxifene hydrochloride;   Other: Lactose Capsules
20 Recruiting Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: Raloxifene hydrochloride;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.